Ziopharm Oncology gets approval for brain cancer study

Ziopharm Oncology (ZIOP) gets approval from the RAC to run a Phase 1 study of Ad-RTS-IL-12 in brain cancer.

The company expects to launch the study in H1 of next year.

Ad-RTS-IL-12 is in Phase 2 testing for melanoma and breast cancer. (PR)

Reminder: Ad-RTS-IL-12 is developed with a controlled expression platform from Intrexon (XON).

ZIOP +10.3% premarket

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs